A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

Bristol-Myers Squibb (BMS)

Status and phase

Enrolling

Phase 1

Conditions

Metastatic Castration-resistant Prostate Cancer

Treatments

Drug: BMS-986460

Study type

Interventional

Funder types

Industry

Identifiers

NCT06067841

CA125-1008

Details and patient eligibility

About

The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.

Enrollment

90 estimated patients

Sex

Male

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Participant must have histologically or cytologically confirmed adenocarcinoma of the prostate.
Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.
Participant must have prostate specific antigen (PSA) of ≥ 2 ng/mL at Screening
Participant must have progressed on androgen deprivation therapy (ADT) and at least one prior secondary hormonal therapy approved for castration-resistant prostate cancer (CRPC)

Exclusion criteria

Participant must not have history of brain metastases.
Participant must not have impaired cardiac function or clinically significant cardiac disease.
Participant must not have any significant medical condition, including active or uncontrolled infection, psychiatric illness, or the presence of laboratory abnormalities, which places the participant at unacceptable risk or prevent participation in the study based on Investigator assessment.

Other protocol-defined inclusion/exclusion criteria apply